Cancer Forums and News by PhD's

News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

No magic tomato? Study breaks link between lycopene and prostate cancer prevention
By Dross at 2007-05-17 22:09

Tomatoes might be nutritious and tasty, but don’t count on them to prevent prostate cancer. In the May issue of Cancer Epidemiology, Biomarkers & Prevention, researchers based at the National Cancer Institute and Fred Hutchinson Cancer Research Center report that lycopene, an antioxidant predominately found in tomatoes, does not effectively prevent prostate cancer. In fact, the researchers noted an association between beta-carotene, an antioxidant related to lycopene, and an increased risk for aggressive prostate cancer.

According to the researchers, the study is one of the largest to evaluate the role of blood concentrations of lycopene and other carotenoid antioxidants in preventing prostate cancer. Study data were derived from over 28,000 men enrolled in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, an ongoing, randomized National Cancer Institute trial to evaluate cancer screening methods and to investigate early markers of cancer.

read more | 1368 reads

Heavy multivitamin use may be linked to advanced prostate cancer
By Dross at 2007-05-16 00:11

While regular multivitamin use is not linked with early or localized prostate cancer, taking too many multivitamins may be associated with an increased risk for advanced or fatal prostate cancers, according to a study in the May 16 issue of the Journal of the National Cancer Institute.

Millions of Americans take multivitamins because of a belief in their potential health benefits, even though there is limited scientific evidence that they prevent chronic disease. Researchers have wondered what impact multivitamin use might have on cancer risk.

Karla Lawson, Ph.D., of the National Cancer Institute in Bethesda, Md., and colleagues followed 295,344 men enrolled in the National Institutes of Health-AARP Diet and Health Study to determine the association between multivitamin use and prostate cancer risk. After five years of follow-up, 10,241 men were diagnosed with prostate cancer, including 8,765 with localized cancers and 1,476 with advanced cancers.

read more | 2 comments | 946 reads

Quick, Innovative Procedure Helps Men Minimize Incontinence After Prostatectomy
By Dross at 2007-05-14 21:48

housands of men facing surgical removal of the prostate due to cancer may someday have one less thing to worry about: post-surgical urinary incontinence.

That's because a team of expert urologic surgeons at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has devised a simple, effective means of reconstructing key anatomical structures that ensure continence.

They describe the success of the procedure in the journal Urology.

"Modifying existing tissues, our technique added only a few minutes to standard robotic prostatectomy, yet attained a 95 percent continence rate among patients 16 weeks after their surgeries," explains lead researcher Dr. Ashutosh K. Tewari, director of robotic prostatectomy and outcomes research at NewYork-Presbyterian/Weill Cornell and the Ronald P. Lynch Associate Professor of Urologic Oncology at Weill Cornell Medical College.

read more | 829 reads

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and
By Dross at 2007-04-26 00:46



Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) , a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) confirms that a mouse equivalent to Peregrine's novel monoclonal antibodyterm bavituximab given in combination with docetaxel decreased the growth of common forms of prostate cancer significantly more than either agent alone. This increase in anti-tumor efficacy was achieved with no apparent increase in toxicity. Researchers also observed that in one tumor model, the combination significantly decreased the level of serum PSA, a biomarker for prostate cancer, and in both tumor types tested it was more effective in decreasing the density of the microvessels needed to support tumor growth and development.

"This data reaffirms the potential of bavituximab for the treatment of prostate cancer in combination with docetaxel and is particularly timely since we recently completed enrollment in our first human trial of bavituximab in combination with anti-cancer agents including docetaxel," said Steven W. King, president and CEO of Peregrine. "We look forward to assessing further bavituximab's anti-cancer potential in our ongoing clinical trials, as well as in new combination therapy clinical studies we will be initiating later this year."

read more | 1332 reads

UCLA study finds prostate cancer treatments impact on quality of life
By Dross at 2007-04-24 21:30

A rigorous, long-term study of quality of life in patients who underwent one of the three most common treatments for prostate cancer found that each affected men's lives in different ways. The findings provide invaluable information for men with prostate cancer who are facing vital treatment decisions.

Researchers studied quality of life in men who either underwent radical prostatectomy, implantation of radioactive seeds in their prostate gland or had external beam radiation therapy. The three treatment options rank about equally in survival outcomes for most men, so specific impacts on quality of life become paramount in making treatment decisions, said Dr. Mark Litwin, the study's lead author and a researcher at UCLA's Jonsson Cancer Center.

read more | 985 reads

New imaging method shows whether treatment for advanced prostate cancer is working
By Dross at 2007-04-16 23:08

New imaging method shows whether treatment for advanced prostate cancer is working, U-M study finds

Measuring diffusion of water in tissue indicates early on if tumors shrink

ANN ARBOR, Mich. - Researchers at the University of Michigan Comprehensive Cancer Center have identified a new imaging technique that can measure the effectiveness of treatment for prostate cancer that has spread to the bones. The technique involves measuring diffusion of water within tumors.

read more | 1183 reads

PSA doubling predicts prostate cancer recurrence
By Dross at 2007-04-11 01:57

A detectable level of prostate-specific antigen (PSA) is the first indicator of recurrent prostate cancer after radical prostatectomy. In a new Mayo Clinic study, the concept of PSA doubling time (DT) is found to be a reliable tool to distinguish which patients have prolonged innocuous PSA levels after therapy from those who are at great risk for disease recurrence and death from prostate cancer. Doubling time is defined as the duration for PSA levels in the blood to increase by 100 percent.

Mayo’s study, published in the April issue of Mayo Clinic Proceedings, concludes that patients with a PSA doubling time of less than three months after therapy are at imminent risk of death from prostate cancer. Patients with a doubling time of three to 12 months are at a significant risk for the development of systematic disease and cancer-specific death.

read more | 1335 reads

Stress may help cancer cells resist treatment, research shows
By Dross at 2007-04-11 01:56

Scientists from Wake Forest University School of Medicine are the first to report that the stress hormone epinephrine causes changes in prostate and breast cancer cells that may make them resistant to cell death.

"These data imply that emotional stress may contribute to the development of cancer and may also reduce the effectiveness of cancer treatments," said George Kulik, D.V.M., Ph.D., an assistant professor of cancer biology and senior researcher on the project.

The study results are reported on-line in the Journal of Biological Chemistry and will appear in a future print issue.

read more | 724 reads

Measuring calcium intake can help to identify osteoporosis in men with prostate cancer
By Dross at 2007-04-11 01:55

Measuring a man’s daily calcium intake is an effective way of identifying prostate cancer patients with a higher than average risk of osteoporosis, according to the April issue of the urology journal BJU International.

Researchers from the Autonoma University School of Medicine, Barcelona, Spain, looked at a cross-section of 372 men with prostate cancer. 72 per cent were receiving androgen-deprivation therapy (ADT) and 28 per cent had undergone a radical prostatectomy. Their average age was just under 70.

They found that 49 per cent of the men had osteoporosis, including 55 per cent of those who had received the ADT hormone therapy and 35 per cent of those who had had a prostatectomy.

read more | 724 reads

The Need for Better Dissemination of Clinical Trial Information and Opportunities
By HCat at 2007-04-06 06:59

    The National Prostate Cancer Coalition (NPCC) has started the G.A.M.E. (Get All Men Educated) program after a recent report from the Coalition of Cancer Cooperative Groups and Northwestern University. The report is a survey of 1,788 cancer survivors in the US in order to understand the range of awareness about cancer clinical trials. This is the link to the study Cancer Clinical Trials Awareness and Attitudes in Cancer Survivors. The G.A.M.E. program was started because the report showed that only 12% of men with prostate cancer know that clinical trials are an option.

read more | 1480 reads

Study identifies multiple genetic risk factors for prostate cancer
By Dross at 2007-04-02 22:12

A study led by researchers at the Keck School of Medicine of the University of Southern California (USC) and Harvard Medical School has identified seven genetic risk factors—DNA sequences carried by some people but not others—that predict risk for prostate cancer. According to the study's findings, these risk factors are clustered in a single region of the human genome on chromosome 8 and powerfully predict a man's probability of developing prostate cancer. The paper will be published in the online edition of Nature Genetics on April 1.

"The study has identified combinations of genetic variants that predict more than a fivefold range of risk for prostate cancer," says senior author David Reich, assistant professor of genetics at Harvard Medical School and associate member of the Broad Institute of Harvard and MIT. "Both high- and low-risk combinations of variants are common in human populations."

read more | 1206 reads

Curecumin(TM) May Be an Effective Treatment for Prostate Cancer
By Dross at 2007-03-21 00:40



"Curcumin, a turmeric root extract, has been shown to possess activity in the treatment and prevention of cancer, multiple sclerosis, and Alzheimer's disease," according to a 3/7/2007 article posted on "The molecular mechanism for its anticancer effect is largely unknown, although it is thought to inhibit the synthesis of MDM2, an oncoprotein known to bind p53 and modulate p21 expression. In the March 1 issue of Cancer Research, Li and colleagues from the Comprehensive Cancer Center of the University of Alabama report on a study designed to elucidate the molecular anticancer effect of curcumin in a preclinical prostate cancer model." "Curcumin was found to decrease the mRNA and protein expression of the oncoprotein MDM2 and to enhance the expression of tumor modulator p21." "This well-performed study provides an elegant mechanistic explanation for the anticancer effect of curcumin."

read more | 992 reads

Inflammation may play role in metastasis of prostate cancer
By Dross at 2007-03-19 03:11

Many would assume that "mounting an immune response" or "having your body fight the cancer" is a good thing. Now, research at the University of California, San Diego (UCSD) School of Medicine strongly suggests that inflammation associated with the progression of tumors actually plays a key role in the metastasistermterm of prostate cancer.

The research, appearing online March 19 in advance of publication in the journal Nature, identifies a mechanism which triggers metastasis, which is the spread of cancer in late stages of prostate cancer development. The findings by Michael Karin, Ph.D., professor of pharmacology in UCSD's Laboratory of Gene Regulation and Signal Transduction, and colleagues may help solve the puzzle of why it takes so long for cancer to metastasize, as well as what causes it to do so. Furthermore, this new work may lead to development of anti-metastaticterm therapies.

read more | 1 comment | 818 reads

Soy found protective against localized prostate cancer
By Dross at 2007-03-17 02:07

The largest study examining the relationship between the traditional soy-rich Japanese diet and development of prostate cancer in Japanese men has come to a seemingly contradictory conclusion: intake of isoflavone chemicals, derived largely from soy foods, decreased the risk of localized prostate cancer but increased the risk of advanced prostate cancer.

The prospective study of 43,509 men, published in the March issue of Cancer Epidemiology, Biomarkers & Prevention, suggests that the effects of isoflavones on prostate cancer development may differ according to disease stage, say researchers at the National Cancer Center in Japan.

read more | 1083 reads

Obesity at the Time of Prostate-Cancer Diagnosis Dramatically Increases the Risk of Dying From the Disease
By Dross at 2007-03-15 01:17

Obese men who are diagnosed with prostate cancer have more than two-and-a-half times the risk of dying from the disease as compared to men of normal weight at the time of diagnosis, according to a study by researchers at Fred Hutchinson Cancer Research Center. The findings by senior author Alan Kristal, Dr.P.H., and colleagues appear online and will be published in the March 15 print edition of the journal Cancer.

"I was very surprised by the findings," said Kristal, member and associate head of the Cancer Prevention Program in the Hutchinson Center's Public Health Sciences Division. "We found the prostate-cancer-specific mortality risk associated with obesity was similar regardless of treatment, disease grade or disease stage at the time of diagnosis," he said.

read more | 833 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 05:05 PM.